🚀 VC round data is live in beta, check it out!
Emvision Valuation Multiples
Discover revenue and EBITDA valuation multiples for Emvision and similar public comparables like Fonar, Hyperfine, Onyx Healthcare, Paxman and more.
Emvision Overview
About Emvision
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury.
Founded
2017
HQ
Employees
N/A
Website
Financials (LTM)
EV
$110M
Emvision Financials
Emvision reported last 12-month revenue of $4M and negative EBITDA of ($6M).
In the same LTM period, Emvision generated ($6M) in EBITDA losses and had net loss of ($6M).
Revenue (LTM)
Emvision P&L
In the most recent fiscal year, Emvision reported revenue of — and net income of —.
Emvision expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | — | XXX | XXX | XXX |
| EBITDA | ($6M) | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (153%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (160%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | — | XXX | XXX | XXX |
| Net Margin | (168%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Emvision Stock Performance
Emvision has current market cap of $115M, and enterprise value of $110M.
Market Cap Evolution
Emvision's stock price is $1.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $110M | $115M | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEmvision Valuation Multiples
Emvision trades at 29.0x EV/Revenue multiple, and (18.9x) EV/EBITDA.
EV / Revenue (LTM)
Emvision Financial Valuation Multiples
As of March 23, 2026, Emvision has market cap of $115M and EV of $110M.
Equity research analysts estimate Emvision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Emvision has a P/E ratio of (18.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $115M | XXX | $115M | XXX | XXX | XXX |
| EV (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV/Revenue | 29.0x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (18.9x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (18.1x) | XXX | — | XXX | XXX | XXX |
| P/E | (18.0x) | XXX | — | XXX | XXX | XXX |
| EV/FCF | (19.7x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Emvision Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Emvision Margins & Growth Rates
Emvision's revenue in the last 12 month declined by (5%).
Emvision's rule of 40 is (158%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Emvision's rule of X is (166%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Emvision Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (5%) | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | (153%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 75% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (158%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (166%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | 35% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 80% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Emvision Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fonar | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyperfine | XXX | XXX | XXX | XXX | XXX | XXX |
| Onyx Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Paxman | XXX | XXX | XXX | XXX | XXX | XXX |
| Treace Medical Concepts | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emvision M&A Activity
Emvision acquired XXX companies to date.
Last acquisition by Emvision was on XXXXXXXX, XXXXX. Emvision acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Emvision
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEmvision Investment Activity
Emvision invested in XXX companies to date.
Emvision made its latest investment on XXXXXXXX, XXXXX. Emvision invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Emvision
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Emvision
| When was Emvision founded? | Emvision was founded in 2017. |
| Where is Emvision headquartered? | Emvision is headquartered in Australia. |
| Is Emvision publicly listed? | Yes, Emvision is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Emvision? | Emvision trades under EMV ticker. |
| When did Emvision go public? | Emvision went public in 2018. |
| Who are competitors of Emvision? | Emvision main competitors are Fonar, Hyperfine, Onyx Healthcare, Paxman. |
| What is the current market cap of Emvision? | Emvision's current market cap is $115M. |
| What is the current revenue of Emvision? | Emvision's last 12 months revenue is $4M. |
| What is the current revenue growth of Emvision? | Emvision revenue growth (NTM/LTM) is (5%). |
| What is the current EV/Revenue multiple of Emvision? | Current revenue multiple of Emvision is 29.0x. |
| Is Emvision profitable? | No, Emvision is not profitable. |
| What is the current EBITDA of Emvision? | Emvision has negative EBITDA and is not profitable. |
| What is Emvision's EBITDA margin? | Emvision's last 12 months EBITDA margin is (153%). |
| What is the current EV/EBITDA multiple of Emvision? | Current EBITDA multiple of Emvision is (18.9x). |
| What is the current FCF of Emvision? | Emvision's last 12 months FCF is ($6M). |
| What is Emvision's FCF margin? | Emvision's last 12 months FCF margin is (147%). |
| What is the current EV/FCF multiple of Emvision? | Current FCF multiple of Emvision is (19.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.